Literature DB >> 17487447

Major flares in women with SLE on combined oral contraception.

D A Whitelaw1, S J Jessop2.   

Abstract

Two recent trials concluded that the use of oral contraceptives (OC) did not induce flares in lupus patients. We record our experience with OC in patients with stable lupus. Eight patients were enrolled in an open trial. Six received a combined contraceptive pill and two were allocated to the control arm. During a 12 month follow-up, 3 patients in the active arm experienced 4 major flares. One patient died as a result of uncontrolled disease complicated by sepsis. At this point, we abandoned the trial. The 2 patients in the control arm experienced no disease exacerbation during the 7 months of observation. We would urge that patients who are placed on OC be closely monitored.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17487447     DOI: 10.1007/s10067-007-0641-y

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  15 in total

1.  Estrogen metabolites: increasing evidence for their role in rheumatoid arthritis and systemic lupus erythematosus.

Authors:  Maurizio Cutolo
Journal:  J Rheumatol       Date:  2004-03       Impact factor: 4.666

2.  Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE.

Authors:  C Bombardier; D D Gladman; M B Urowitz; D Caron; C H Chang
Journal:  Arthritis Rheum       Date:  1992-06

3.  Differences by race, sex and age in the clinical and immunologic features of recently diagnosed systemic lupus erythematosus patients in the southeastern United States.

Authors:  G S Cooper; C G Parks; E L Treadwell; E W St Clair; G S Gilkeson; P L Cohen; R A S Roubey; M A Dooley
Journal:  Lupus       Date:  2002       Impact factor: 2.911

4.  Baseline characteristics of a multiethnic lupus cohort: PROFILE.

Authors:  G S Alarcón; G McGwin; M Petri; J D Reveille; R Ramsey-Goldman; R P Kimberly
Journal:  Lupus       Date:  2002       Impact factor: 2.911

5.  Combined oral contraceptives in women with systemic lupus erythematosus.

Authors:  Michelle Petri; Mimi Y Kim; Kenneth C Kalunian; Jennifer Grossman; Bevra H Hahn; Lisa R Sammaritano; Michael Lockshin; Joan T Merrill; H Michael Belmont; Anca D Askanase; W Joseph McCune; Michelene Hearth-Holmes; Mary Anne Dooley; Joan Von Feldt; Alan Friedman; Mark Tan; John Davis; Mary Cronin; Betty Diamond; Meggan Mackay; Lisa Sigler; Michael Fillius; Ann Rupel; Frederick Licciardi; Jill P Buyon
Journal:  N Engl J Med       Date:  2005-12-15       Impact factor: 91.245

6.  A trial of contraceptive methods in women with systemic lupus erythematosus.

Authors:  Jorge Sánchez-Guerrero; América G Uribe; Luisa Jiménez-Santana; Marilú Mestanza-Peralta; Pilar Lara-Reyes; Armando H Seuc; María-del-Carmen Cravioto
Journal:  N Engl J Med       Date:  2005-12-15       Impact factor: 91.245

7.  Influence of oral contraceptive therapy on the activity of systemic lupus erythematosus.

Authors:  P Jungers; M Dougados; C Pélissier; F Kuttenn; F Tron; P Lesavre; J F Bach
Journal:  Arthritis Rheum       Date:  1982-06

8.  Oral contraceptives in systemic lupus erythematosus: side-effects and influence on the activity of SLE.

Authors:  H A Julkunen
Journal:  Scand J Rheumatol       Date:  1991       Impact factor: 3.641

9.  Definition, incidence, and clinical description of flare in systemic lupus erythematosus. A prospective cohort study.

Authors:  M Petri; M Genovese; E Engle; M Hochberg
Journal:  Arthritis Rheum       Date:  1991-08

10.  The occurrence, nature and distribution of flares in a cohort of patients with systemic lupus erythematosus: a rheumatological view.

Authors:  M R Ehrenstein; S E Conroy; J Heath; D S Latchman; D A Isenberg
Journal:  Br J Rheumatol       Date:  1995-03
View more
  2 in total

Review 1.  The multi-faceted influences of estrogen on lymphocytes: toward novel immuno-interventions strategies for autoimmunity management.

Authors:  Ebru Karpuzoglu; Moncef Zouali
Journal:  Clin Rev Allergy Immunol       Date:  2011-02       Impact factor: 8.667

2.  Current awareness: pharmacoepidemiology and drug safety.

Authors: 
Journal:  Pharmacoepidemiol Drug Saf       Date:  2008-06       Impact factor: 2.890

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.